Iron Poisoning

• FDA approval · 2025-05-08
  FDA Approved: DEFEROXAMINE MESYLATE — Supplemental Application (Hospira, Inc.)

  FDA approved a supplemental application for Deferoxamine Mesylate (Hospira, Inc.), a generic iron chelator.

• FDA approval · 2024-02-05
  FDA Approved: DEFEROXAMINE MESYLATE — Supplemental Application (Apotex Corp.)

  The FDA approved a supplemental ANDA for deferoxamine mesylate submitted by Apotex Corp.

• FDA approval · 2023-11-28
  FDA Approved: DEFEROXAMINE — Supplemental Application (Fresenius Kabi USA, LLC)

  FDA approved a supplemental application for Deferoxamine (deferoxamine mesylate) submitted by Fresenius Kabi USA, LLC.

• FDA approval · 2023-10-23
  FDA Approved: DEFEROXAMINE MESYLATE — Supplemental Application (Hospira, Inc.)

  FDA approves a supplemental application for deferoxamine mesylate (Hospira) under ANDA076019.

• FDA approval · 2017-09-29
  FDA Approved: DEFEROXAMINE MESYLATE — Original Application (Apotex Corp.)

  FDA approved Apotex Corp's generic deferoxamine mesylate (Deferoxamine Mesylate) under an original ANDA for the treatment of iron overload d…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2016-11-08
  FDA Approved: DEFEROXAMINE MESYLATE — Supplemental Application (Hospira, Inc.)

  FDA approved a supplemental application for deferoxamine mesylate by Hospira, Inc., supporting the availability of a generic product.

• FDA label_change · 2012-07-18
  FDA Approved: DEFEROXAMINE — Supplemental Application (Fresenius Kabi USA, LLC)

  FDA approved a supplemental application for Deferoxamine (Deferoxamine Mesylate) from Fresenius Kabi USA, LLC, likely involving changes to l…

• FDA approval · 2012-06-20
  FDA Approved: DEFEROXAMINE — Supplemental Application (Fresenius Kabi USA, LLC)

  FDA approved a supplemental application for Deferoxamine Mesylate (Deferoxamine) from Fresenius Kabi USA, LLC.

• FDA approval · 2011-12-16
  FDA Approved: DESFERAL — Supplemental Application (MITEM PHARMA)

  The FDA approved a supplemental application for DESFERAL (deferoxamine mesylate) submitted by Mitem Pharma.

• FDA approval · 2011-05-27
  FDA Approved: DEFEROXAMINE — Supplemental Application (Fresenius Kabi USA, LLC)

  FDA approved a supplemental application for deferoxamine mesylate from Fresenius Kabi USA, LLC.

• FDA approval · 2010-09-07
  FDA Approved: DESFERAL — Supplemental Application (MITEM PHARMA)

  The FDA approved a supplemental application for DESFERAL (deferoxamine mesylate) from MITEM PHARMA, indicating regulatory action to modify/e…

• FDA approval · 2009-09-15
  FDA Approved: DEFEROXAMINE — Original Application (Fresenius Kabi USA, LLC)

  FDA approved Deferoxamine mesylate as a generic product under Original Application by Fresenius Kabi USA, LLC.

• FDA approval · 2007-12-14
  FDA Approved: DEFEROXAMINE MESYLATE — Supplemental Application (Hospira, Inc.)

  FDA approved Hospira's supplemental application for Deferoxamine Mesylate, enabling its continued marketing as an iron chelation therapy.